UNSPSC 51111838: Bortezomib

This classification denotes a proteasome inhibitor with the molecular formula C19H25BN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69G8BD63PP, chemically known as boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (s-(r*,s*))- but generally known as bortezomib, which bears US NIH Compound Identifier 93860. European Medicines Agency schedules Bortezomib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20020.

I cannot write a summary of UNSPSC 51111838 Bortezomib as a Commodity code for state and local procurement activity. The source provides no recent contract opportunities, issuing bodies, geographic activity, or scope description. Bortezomib is a pharmaceutical product (a proteasome inhibitor used in cancer treatment) that does not appear in the state and local procurement market through standard RFP, RFQ, IFB, or ITT processes—it is typically procured through GPO contracts, Medicaid pharmacy networks, or direct hospital purchasing agreements outside the public notice channels that populate state and local opportunity databases. Without documented recent solicitations under this code from counties, cities, school districts, transit authorities, or state agencies, no actionable summary can be written.